<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>488-SULFAMETHOXAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
<ATC code="J01EE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>488-SULFAMETHOXAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
<ATC code="J01EE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the antibacterial sulfonamide and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
